Osseous metastases are frequently observed in association with breast carcinoma. The neurological defects produced by spinal cord compression or nerve root compression because of osseous metastasis are occasionally seen and are refractory. Usually, paralysis which occurs more than 24-48 hours after the onset is irreversible, and the patient is unlikely to recover no matter what therapeutic procedures are performed. We herein present a case of pelvic metastasis from breast carcinoma. Dysuria of the patient caused by damage to the lower urination center located in the sacral spinal cord was alleviated by multi-modality therapy with zoledronic acid (ZOL).A 58-year-old woman was admitted to the hospital to be treated for complete urinary retention. The patient had experienced left gluteal pain for 4 months. Irradiating pain in the thigh was also recognized. A subsequent dynamic magnetic resonance imaging examination demonstrated a pelvic tumor. A histopathological examination of a needle biopsy specimen of the pelvic tumor showed that the tumor appeared to be a metastatic adenocarcinoma, which was most likely to be a metastasis of breast carcinoma because estrogen receptor was positive, while CK7 and CK20 were negative. A 20-mm breast carcinoma in the lower-lateral quadrant of the breast was diagnosed by a pathological study of a core needle biopsy specimen. The pelvic metastasis from the breast carcinoma was confirmed, because, histopathologically, the cancer cells were similar to that of the pelvic tumor showing low atypical cells and mitotic figures and, immunohistochemically, both the breast and the pelvis tumor were estrogen receptor positive, progesterone receptor negative and C-erbB-2 negative. No other disease was detected in any organ. The breast carcinoma was not resected because it was unlikely to change the prognosis of the patient. Initially, the intravesical pressure was decompressed with bladder catheterization. A week after admission, radiotherapy was administered with 50 Gy to the pelvic tumor. Subsequently, endocrine therapy using 25 mg ⁄ day exemestane, aromatase inhibitor and bisphosphonate therapy using 90 mg pamidronate disodium per month was administered. In the meantime, the patient was given distigmine bromide (quaternary ammonium base) and urapidil (a1-blocker). Intermittent self-catheterization was not administered because of discomfort. Two months after the initiation of the therapy, an intrathecal phenol block was administered because of the ongoing gluteal pain and irradiating pain to the thigh. Three months after admission, ZOL 4 mg ⁄ month was administered in place of pamidronate disodium. Two days later the patient felt uresiesthesia and was able to urinate with no residual urine a month after the first treatment of ZOL. The dysuria disappeared completely and has not flared up again for 2 years, although some slight gluteral pain has been still observed. The pelvic tumor and breast tumor showed approximately 47% and 55% shrinkage, respectively ( Figs. 1 and 2).In breast carcinoma, oss...